share_log

Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target

Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target

Chardan Capital重申买入增益疗法,维持6美元的目标股价
Benzinga ·  03/27 04:38

Chardan Capital analyst Keay Nakae reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $6 price target.

Chardan Capital分析师Keay Nakae重申Gain Therapeutics(纳斯达克股票代码:GANX)的买入并维持6美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发